APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oligonucleotide CDMO Industry Growth and Trends Forecast to 2032

Report ID 174201460115 April 2026122 pages

Choose your research edition.

Industry ResearchOligonucleotide CDMO Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide CDMO Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Oligonucleotide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide CDMO Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

According to APO Research, the global Oligonucleotide CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligonucleotide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Oligonucleotide CDMO market include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI and Veliter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oligonucleotide CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oligonucleotide CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oligonucleotide CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oligonucleotide CDMO.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Oligonucleotide CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oligonucleotide CDMO Market by Company

Agilent

ST Pharm

Bachem

BioSpring

Creative Biogene

Sylentis

Ajinomoto Bio-Pharma

EUROAPI

Veliter

PolyPeptide Group

CordenPharma

Thermofischer

Bio Basic

Genscript

Cytiva

ScinoPharm

CBL

Piramal Pharma

CPC Scientific

Eurogentec

Cambrex

WuXi STA

Oligonucleotide CDMO Segment by Type

APIs and Intermediates

FDF

Oligonucleotide CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Oligonucleotide CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Oligonucleotide CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide CDMO Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Oligonucleotide CDMO Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Oligonucleotide CDMO Market Share by Region (2021-2026) Table 4. Global Oligonucleotide CDMO Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Oligonucleotide CDMO Market Share by Region (2027-2032) Table 6. Global Oligonucleotide CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Oligonucleotide CDMO Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Oligonucleotide CDMO Market Size Share by Type (2021-2026) Table 9. Global Oligonucleotide CDMO Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Oligonucleotide CDMO Market Size Share Forecasted by Type (2027-2032) Table 11. North America Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Oligonucleotide CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Oligonucleotide CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Oligonucleotide CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Oligonucleotide CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Oligonucleotide CDMO Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Oligonucleotide CDMO Market Size Share by Application (2021-2026) Table 24. Global Oligonucleotide CDMO Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Oligonucleotide CDMO Market Size Share Forecasted by Application (2027-2032) Table 26. North America Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Oligonucleotide CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Oligonucleotide CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Oligonucleotide CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Oligonucleotide CDMO Industry Trends Table 37. Oligonucleotide CDMO Industry Drivers Table 38. Oligonucleotide CDMO Industry Opportunities and Challenges Table 39. Oligonucleotide CDMO Industry Restraints Table 40. Global Oligonucleotide CDMO Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Oligonucleotide CDMO Revenue Market Share by Company (2021-2026) Table 42. Global Oligonucleotide CDMO Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Oligonucleotide CDMO Key Company Headquarters & Area Served Table 44. Global Oligonucleotide CDMO Company, Product Type & Application Table 45. Global Oligonucleotide CDMO Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Oligonucleotide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Agilent Company Information Table 49. Agilent Business Overview Table 50. Agilent Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Agilent Oligonucleotide CDMO Product Portfolio Table 52. Agilent Recent Development Table 53. ST Pharm Company Information Table 54. ST Pharm Business Overview Table 55. ST Pharm Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. ST Pharm Oligonucleotide CDMO Product Portfolio Table 57. ST Pharm Recent Development Table 58. Bachem Company Information Table 59. Bachem Business Overview Table 60. Bachem Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Bachem Oligonucleotide CDMO Product Portfolio Table 62. Bachem Recent Development Table 63. BioSpring Company Information Table 64. BioSpring Business Overview Table 65. BioSpring Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. BioSpring Oligonucleotide CDMO Product Portfolio Table 67. BioSpring Recent Development Table 68. Creative Biogene Company Information Table 69. Creative Biogene Business Overview Table 70. Creative Biogene Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Creative Biogene Oligonucleotide CDMO Product Portfolio Table 72. Creative Biogene Recent Development Table 73. Sylentis Company Information Table 74. Sylentis Business Overview Table 75. Sylentis Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Sylentis Oligonucleotide CDMO Product Portfolio Table 77. Sylentis Recent Development Table 78. Ajinomoto Bio-Pharma Company Information Table 79. Ajinomoto Bio-Pharma Business Overview Table 80. Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio Table 82. Ajinomoto Bio-Pharma Recent Development Table 83. EUROAPI Company Information Table 84. EUROAPI Business Overview Table 85. EUROAPI Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. EUROAPI Oligonucleotide CDMO Product Portfolio Table 87. EUROAPI Recent Development Table 88. Veliter Company Information Table 89. Veliter Business Overview Table 90. Veliter Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Veliter Oligonucleotide CDMO Product Portfolio Table 92. Veliter Recent Development Table 93. PolyPeptide Group Company Information Table 94. PolyPeptide Group Business Overview Table 95. PolyPeptide Group Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. PolyPeptide Group Oligonucleotide CDMO Product Portfolio Table 97. PolyPeptide Group Recent Development Table 98. CordenPharma Company Information Table 99. CordenPharma Business Overview Table 100. CordenPharma Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. CordenPharma Oligonucleotide CDMO Product Portfolio Table 102. CordenPharma Recent Development Table 103. Thermofischer Company Information Table 104. Thermofischer Business Overview Table 105. Thermofischer Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Thermofischer Oligonucleotide CDMO Product Portfolio Table 107. Thermofischer Recent Development Table 108. Bio Basic Company Information Table 109. Bio Basic Business Overview Table 110. Bio Basic Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Bio Basic Oligonucleotide CDMO Product Portfolio Table 112. Bio Basic Recent Development Table 113. Genscript Company Information Table 114. Genscript Business Overview Table 115. Genscript Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Genscript Oligonucleotide CDMO Product Portfolio Table 117. Genscript Recent Development Table 118. Cytiva Company Information Table 119. Cytiva Business Overview Table 120. Cytiva Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Cytiva Oligonucleotide CDMO Product Portfolio Table 122. Cytiva Recent Development Table 123. ScinoPharm Company Information Table 124. ScinoPharm Business Overview Table 125. ScinoPharm Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. ScinoPharm Oligonucleotide CDMO Product Portfolio Table 127. ScinoPharm Recent Development Table 128. CBL Company Information Table 129. CBL Business Overview Table 130. CBL Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. CBL Oligonucleotide CDMO Product Portfolio Table 132. CBL Recent Development Table 133. Piramal Pharma Company Information Table 134. Piramal Pharma Business Overview Table 135. Piramal Pharma Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Piramal Pharma Oligonucleotide CDMO Product Portfolio Table 137. Piramal Pharma Recent Development Table 138. CPC Scientific Company Information Table 139. CPC Scientific Business Overview Table 140. CPC Scientific Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. CPC Scientific Oligonucleotide CDMO Product Portfolio Table 142. CPC Scientific Recent Development Table 143. Eurogentec Company Information Table 144. Eurogentec Business Overview Table 145. Eurogentec Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Eurogentec Oligonucleotide CDMO Product Portfolio Table 147. Eurogentec Recent Development Table 148. Cambrex Company Information Table 149. Cambrex Business Overview Table 150. Cambrex Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Cambrex Oligonucleotide CDMO Product Portfolio Table 152. Cambrex Recent Development Table 153. WuXi STA Company Information Table 154. WuXi STA Business Overview Table 155. WuXi STA Oligonucleotide CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. WuXi STA Oligonucleotide CDMO Product Portfolio Table 157. WuXi STA Recent Development Table 158. North America Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America Oligonucleotide CDMO Market Size by Country (2021-2026) & (US$ Million) Table 160. North America Oligonucleotide CDMO Market Share by Country (2021-2026) Table 161. North America Oligonucleotide CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America Oligonucleotide CDMO Market Share Forecast by Country (2027-2032) Table 163. Europe Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Oligonucleotide CDMO Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Oligonucleotide CDMO Market Share by Country (2021-2026) Table 166. Europe Oligonucleotide CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Oligonucleotide CDMO Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Oligonucleotide CDMO Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific Oligonucleotide CDMO Market Share by Country (2021-2026) Table 171. Asia-Pacific Oligonucleotide CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific Oligonucleotide CDMO Market Share Forecast by Country (2027-2032) Table 173. Latin America Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Latin America Oligonucleotide CDMO Market Size by Country (2021-2026) & (US$ Million) Table 175. Latin America Oligonucleotide CDMO Market Share by Country (2021-2026) Table 176. Latin America Oligonucleotide CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Latin America Oligonucleotide CDMO Market Share Forecast by Country (2027-2032) Table 178. Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East & Africa Oligonucleotide CDMO Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East & Africa Oligonucleotide CDMO Market Share by Country (2021-2026) Table 181. Middle East & Africa Oligonucleotide CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East & Africa Oligonucleotide CDMO Market Share Forecast by Country (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Oligonucleotide CDMO Product Image Figure 3. Global Oligonucleotide CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Oligonucleotide CDMO Market Size (2021-2032) & (US$ Million) Figure 5. Global Oligonucleotide CDMO Market Share by Region: 2025 VS 2032 Figure 6. Global Oligonucleotide CDMO Market Share by Region (2021-2032) Figure 7. North America Oligonucleotide CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Oligonucleotide CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Oligonucleotide CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. APIs and Intermediates Image Figure 13. Global APIs and Intermediates Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. FDF Image Figure 15. Global FDF Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Oligonucleotide CDMO Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Oligonucleotide CDMO Market Share by Type 2025 VS 2032 Figure 18. North America Oligonucleotide CDMO Market Size Share by Type (2021-2032) Figure 19. Europe Oligonucleotide CDMO Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Oligonucleotide CDMO Market Size Share by Type (2021-2032) Figure 21. Latin America Oligonucleotide CDMO Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Oligonucleotide CDMO Market Size Share by Type (2021-2032) Figure 23. Pharmaceutical and Biotechnology Companies Image Figure 24. Global Pharmaceutical and Biotechnology Companies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Research Institutes Image Figure 26. Global Research Institutes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Oligonucleotide CDMO Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Oligonucleotide CDMO Market Share by Application 2025 VS 2032 Figure 31. North America Oligonucleotide CDMO Market Size Share by Application (2021-2032) Figure 32. Europe Oligonucleotide CDMO Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Oligonucleotide CDMO Market Size Share by Application (2021-2032) Figure 34. Latin America Oligonucleotide CDMO Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Oligonucleotide CDMO Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Oligonucleotide CDMO Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Oligonucleotide CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Oligonucleotide CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Oligonucleotide CDMO Market Share by Country (2021-2032) Figure 41. Europe Oligonucleotide CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Oligonucleotide CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Oligonucleotide CDMO Market Share by Country (2021-2032) Figure 44. Asia-Pacific Oligonucleotide CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Oligonucleotide CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Oligonucleotide CDMO Market Share by Country (2021-2032) Figure 47. Latin America Oligonucleotide CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Oligonucleotide CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Oligonucleotide CDMO Market Share by Country (2021-2032) Figure 50. Middle East & Africa Oligonucleotide CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Oligonucleotide CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Oligonucleotide CDMO Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • APIs and Intermediates
  • FDF
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes
  • Others
Companies covered
  • Agilent
  • ST Pharm
  • Bachem
  • BioSpring
  • Creative Biogene
  • Sylentis
  • Ajinomoto Bio-Pharma
  • EUROAPI
  • Veliter
  • PolyPeptide Group
  • CordenPharma
  • Thermofischer
  • Bio Basic
  • Genscript
  • Cytiva
  • ScinoPharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Eurogentec
  • Cambrex
  • WuXi STA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Oligonucleotide CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Oligonucleotide CDMO Market Size by Region (2021-2032)
  5. 1.4.1 Global Oligonucleotide CDMO Market Size by Region (2021-2026)
  6. 1.4.2 Global Oligonucleotide CDMO Market Size by Region (2027-2032)
  7. 1.5 Key Regions Oligonucleotide CDMO Market Size (2021-2032)
  8. 1.5.1 North America Oligonucleotide CDMO Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Oligonucleotide CDMO Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Oligonucleotide CDMO Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate (2021-2032)
2 Oligonucleotide CDMO Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 APIs and Intermediates
  3. 2.1.2 FDF
  4. 2.2 Global Oligonucleotide CDMO Market Size by Type
  5. 2.2.1 Global Oligonucleotide CDMO Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Oligonucleotide CDMO Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Oligonucleotide CDMO Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Oligonucleotide CDMO Market Size by Regions
  9. 2.3.1 North America Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Type (2021-2026)
3 Oligonucleotide CDMO Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Pharmaceutical and Biotechnology Companies
  3. 3.1.2 Research Institutes
  4. 3.1.3 Others
  5. 3.2 Global Oligonucleotide CDMO Market Size by Application
  6. 3.2.1 Global Oligonucleotide CDMO Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Oligonucleotide CDMO Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Oligonucleotide CDMO Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Oligonucleotide CDMO Market Size by Regions
  10. 3.3.1 North America Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Oligonucleotide CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Oligonucleotide CDMO Industry Trends
  2. 4.2 Oligonucleotide CDMO Industry Drivers
  3. 4.3 Oligonucleotide CDMO Industry Opportunities and Challenges
  4. 4.4 Oligonucleotide CDMO Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Oligonucleotide CDMO Revenue (2021-2026)
  2. 5.2 Global Oligonucleotide CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Oligonucleotide CDMO Key Company Headquarters & Area Served
  4. 5.4 Global Oligonucleotide CDMO Company, Product Type & Application
  5. 5.5 Global Oligonucleotide CDMO Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Oligonucleotide CDMO Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Oligonucleotide CDMO Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Oligonucleotide CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Agilent
  2. 6.1.1 Agilent Company Information
  3. 6.1.2 Agilent Business Overview
  4. 6.1.3 Agilent Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Agilent Oligonucleotide CDMO Product Portfolio
  6. 6.1.5 Agilent Recent Developments
  7. 6.2 ST Pharm
  8. 6.2.1 ST Pharm Company Information
  9. 6.2.2 ST Pharm Business Overview
  10. 6.2.3 ST Pharm Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 ST Pharm Oligonucleotide CDMO Product Portfolio
  12. 6.2.5 ST Pharm Recent Developments
  13. 6.3 Bachem
  14. 6.3.1 Bachem Company Information
  15. 6.3.2 Bachem Business Overview
  16. 6.3.3 Bachem Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Bachem Oligonucleotide CDMO Product Portfolio
  18. 6.3.5 Bachem Recent Developments
  19. 6.4 BioSpring
  20. 6.4.1 BioSpring Company Information
  21. 6.4.2 BioSpring Business Overview
  22. 6.4.3 BioSpring Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 BioSpring Oligonucleotide CDMO Product Portfolio
  24. 6.4.5 BioSpring Recent Developments
  25. 6.5 Creative Biogene
  26. 6.5.1 Creative Biogene Company Information
  27. 6.5.2 Creative Biogene Business Overview
  28. 6.5.3 Creative Biogene Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Creative Biogene Oligonucleotide CDMO Product Portfolio
  30. 6.5.5 Creative Biogene Recent Developments
  31. 6.6 Sylentis
  32. 6.6.1 Sylentis Company Information
  33. 6.6.2 Sylentis Business Overview
  34. 6.6.3 Sylentis Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Sylentis Oligonucleotide CDMO Product Portfolio
  36. 6.6.5 Sylentis Recent Developments
  37. 6.7 Ajinomoto Bio-Pharma
  38. 6.7.1 Ajinomoto Bio-Pharma Company Information
  39. 6.7.2 Ajinomoto Bio-Pharma Business Overview
  40. 6.7.3 Ajinomoto Bio-Pharma Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio
  42. 6.7.5 Ajinomoto Bio-Pharma Recent Developments
  43. 6.8 EUROAPI
  44. 6.8.1 EUROAPI Company Information
  45. 6.8.2 EUROAPI Business Overview
  46. 6.8.3 EUROAPI Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 EUROAPI Oligonucleotide CDMO Product Portfolio
  48. 6.8.5 EUROAPI Recent Developments
  49. 6.9 Veliter
  50. 6.9.1 Veliter Company Information
  51. 6.9.2 Veliter Business Overview
  52. 6.9.3 Veliter Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Veliter Oligonucleotide CDMO Product Portfolio
  54. 6.9.5 Veliter Recent Developments
  55. 6.10 PolyPeptide Group
  56. 6.10.1 PolyPeptide Group Company Information
  57. 6.10.2 PolyPeptide Group Business Overview
  58. 6.10.3 PolyPeptide Group Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 PolyPeptide Group Oligonucleotide CDMO Product Portfolio
  60. 6.10.5 PolyPeptide Group Recent Developments
  61. 6.11 CordenPharma
  62. 6.11.1 CordenPharma Company Information
  63. 6.11.2 CordenPharma Business Overview
  64. 6.11.3 CordenPharma Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 CordenPharma Oligonucleotide CDMO Product Portfolio
  66. 6.11.5 CordenPharma Recent Developments
  67. 6.12 Thermofischer
  68. 6.12.1 Thermofischer Company Information
  69. 6.12.2 Thermofischer Business Overview
  70. 6.12.3 Thermofischer Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Thermofischer Oligonucleotide CDMO Product Portfolio
  72. 6.12.5 Thermofischer Recent Developments
  73. 6.13 Bio Basic
  74. 6.13.1 Bio Basic Company Information
  75. 6.13.2 Bio Basic Business Overview
  76. 6.13.3 Bio Basic Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Bio Basic Oligonucleotide CDMO Product Portfolio
  78. 6.13.5 Bio Basic Recent Developments
  79. 6.14 Genscript
  80. 6.14.1 Genscript Company Information
  81. 6.14.2 Genscript Business Overview
  82. 6.14.3 Genscript Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Genscript Oligonucleotide CDMO Product Portfolio
  84. 6.14.5 Genscript Recent Developments
  85. 6.15 Cytiva
  86. 6.15.1 Cytiva Company Information
  87. 6.15.2 Cytiva Business Overview
  88. 6.15.3 Cytiva Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Cytiva Oligonucleotide CDMO Product Portfolio
  90. 6.15.5 Cytiva Recent Developments
  91. 6.16 ScinoPharm
  92. 6.16.1 ScinoPharm Company Information
  93. 6.16.2 ScinoPharm Business Overview
  94. 6.16.3 ScinoPharm Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 ScinoPharm Oligonucleotide CDMO Product Portfolio
  96. 6.16.5 ScinoPharm Recent Developments
  97. 6.17 CBL
  98. 6.17.1 CBL Company Information
  99. 6.17.2 CBL Business Overview
  100. 6.17.3 CBL Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 CBL Oligonucleotide CDMO Product Portfolio
  102. 6.17.5 CBL Recent Developments
  103. 6.18 Piramal Pharma
  104. 6.18.1 Piramal Pharma Company Information
  105. 6.18.2 Piramal Pharma Business Overview
  106. 6.18.3 Piramal Pharma Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Piramal Pharma Oligonucleotide CDMO Product Portfolio
  108. 6.18.5 Piramal Pharma Recent Developments
  109. 6.19 CPC Scientific
  110. 6.19.1 CPC Scientific Company Information
  111. 6.19.2 CPC Scientific Business Overview
  112. 6.19.3 CPC Scientific Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 CPC Scientific Oligonucleotide CDMO Product Portfolio
  114. 6.19.5 CPC Scientific Recent Developments
  115. 6.20 Eurogentec
  116. 6.20.1 Eurogentec Company Information
  117. 6.20.2 Eurogentec Business Overview
  118. 6.20.3 Eurogentec Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Eurogentec Oligonucleotide CDMO Product Portfolio
  120. 6.20.5 Eurogentec Recent Developments
  121. 6.21 Cambrex
  122. 6.21.1 Cambrex Company Information
  123. 6.21.2 Cambrex Business Overview
  124. 6.21.3 Cambrex Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Cambrex Oligonucleotide CDMO Product Portfolio
  126. 6.21.5 Cambrex Recent Developments
  127. 6.22 WuXi STA
  128. 6.22.1 WuXi STA Company Information
  129. 6.22.2 WuXi STA Business Overview
  130. 6.22.3 WuXi STA Oligonucleotide CDMO Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 WuXi STA Oligonucleotide CDMO Product Portfolio
  132. 6.22.5 WuXi STA Recent Developments
7 North America
  1. 7.1 North America Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Oligonucleotide CDMO Market Size by Country (2021-2026)
  3. 7.3 North America Oligonucleotide CDMO Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Oligonucleotide CDMO Market Size by Country (2021-2026)
  3. 8.3 Europe Oligonucleotide CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Oligonucleotide CDMO Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Oligonucleotide CDMO Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Oligonucleotide CDMO Market Size by Country (2021-2026)
  3. 10.3 South America Oligonucleotide CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Oligonucleotide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Oligonucleotide CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst